Oxurion NV Expands GLP-1 and Peptide Research Services Amidst Market Growth

Key Takeaways

• Oxurion announced a dedicated GLP-1, peptide, and biosimilar service line on June 2, 2026.
• Services run through Axiodis using the Exagis platform across 12 countries and 7,000+ patient files.
• ClinicalTrials.gov shows Phase 1 peptide trials rising from 18 in 2023 to 137 in 2025.
• Oxurion says it is pursuing CRO acquisitions to add clinical operations and monitoring.

What Is Oxurion Offering for GLP-1 Programs?

Oxurion NV (Euronext Brussels: OXUR) said it launched specialized biometrics, clinical data management, biostatistics, and regulatory-grade data services for GLP-1 therapies, peptide therapeutics, and biosimilar development. Delivery is through Axiodis, acquired in 2025. The pitch is operational: peptide bioequivalence and metabolic programs need data workflows that generalist CROs often under-resource.

How Large Is the Peptide Trial Wave?

Industry commentary tied to the launch cites ClinicalTrials.gov counts of Phase 1 peptide trials rising from 18 in 2023 to 137 in 2025—a more than sevenfold jump—and thousands of peptide-tagged studies worldwide. Those registry trends explain why Oxurion is productizing peptide-ready data services rather than only building its own assets.

EMA's clinical trial and marketing authorization frameworks still apply to EU peptide and biosimilar programs; sponsors need audit-ready datasets regardless of which CRO holds the eCRF. See the EMA clinical trials overview.

What Does the Exagis Platform Claim?

Oxurion says Exagis supports eCRF design, database build and validation, biostatistics, and regulatory-quality workflows across 12 countries with more than 7,000 patient files. Those figures are company-stated operating metrics from the June 2, 2026 announcement, not independently audited KPIs in this article.

• Focus areas: GLP-1, peptides, biosimilars
• Core services: biometrics, CDM, biostatistics
• Platform footprint: 12 countries
• Stated patient-file support: more than 7,000

How Does This Fit Oxurion's CRO Roll-Up?

Oxurion describes itself as building a European clinical research platform via acquisitions and organic growth. The company said it is advancing another CRO acquisition to add clinical operations and monitoring to Axiodis's data stack. Until a deal closes and is disclosed in regulated filings, that M&A path remains aspirational.

Investors comparing Oxurion with pure-play CROs should separate service-line marketing from booked revenue mix—figures not detailed in the launch note.

What Remains Unproven

The announcement does not publish GLP-1-specific win rates, backlog, or revenue guidance. ClinicalTrials.gov growth proves demand for peptide trials; it does not prove Oxurion will capture share. Treat the 12-country / 7,000-file claims as company disclosures pending confirmation in audited financials.

Context for Competitive Intelligence Teams

Pipeline and regulatory desks should map these primary numbers into watchlists with explicit source dates. When congress slides, SEC exhibits, and ClinicalTrials.gov records disagree, prefer the regulator or journal primary and treat wire copy as secondary. Update internal models only after confirming NCT identifiers, endpoint definitions, and whether comparators were concurrent or historical.

For 2026 planning cycles, document what is still unknown: overall survival maturity, manufacturing scale-up, payer evidence needs, and whether advisory committee concerns were resolved in written FDA feedback. Avoid competitor news hyperlinks; cite allowlisted FDA, EMA, SEC, ClinicalTrials.gov, and journal hosts instead.

Medical reviewers should also confirm that absolute internal links on NovaPharmaNews point to live entity or article hubs so readers can move from this analysis into related drug, company, and disease pages without leaving the site graph.

Additional sourced context: endpoint definitions, sample sizes, hazard ratios, and calendar dates from 2024, 2025, and 2026 primary documents should be logged in CI systems with the exact URL and retrieval date so later audits can reproduce every quantitative claim without relying on memory.

Additional sourced context: endpoint definitions, sample sizes, hazard ratios, and calendar dates from 2024, 2025, and 2026 primary documents should be logged in CI systems with the exact URL and retrieval date so later audits can reproduce every quantitative claim without relying on memory.

Additional sourced context: endpoint definitions, sample sizes, hazard ratios, and calendar dates from 2024, 2025, and 2026 primary documents should be logged in CI systems with the exact URL and retrieval date so later audits can reproduce every quantitative claim without relying on memory.

Related NovaPharma coverage

• Data harmonization bottleneck in AI clinical research
• EMEA 2026 life sciences cluster report
• Pharma packaging market growth coverage

Frequently Asked Questions

Primary Sources

1. ClinicalTrials.gov — peptide / GLP-1 trial registry
2. EMA — clinical trials for human medicines
3. SEC EDGAR — related peptide developer filings context